title: A phase 1 study of vorinostat maintenance after autologous transplant in high-risk lymphoma.
abstract: Only a minority of patients with high risk lymphoma will be cured with autologous transplant, so maintenance with vorinostat, an oral agent with activity in relapsed lymphoma, was studied starting day + 60 for 21 consecutive days followed by a week off for up to 11 cycles. Twenty-three patients with lymphoma were treated. Ten patients completed the full 11-cycle treatment plan per protocol, four patients were removed due to progressive disease and seven withdrew or were removed from the study due to toxicities. Despite Prevnar vaccine administration every 2 months for three injections, the mean antibody concentration never reached protective levels (> 0.35 μg/mL). Fatigue and functional well-being measured by Brief Fatigue Inventory and Functional Assessment of Cancer Therapy-General improved significantly from cycle 1 to cycle 7, but depression scores from the Center for Epidemiologic Studies Depression scale did not change. Given the toxicities observed, this broad-spectrum deacetylase inhibitor at this schedule is not optimal for prolonged maintenance therapy.
authors.affiliation: Division of Hematology, Department of Internal Medicine, The Ohio State University , Columbus, OH , USA.
authors.forename: Craig C
authors.initials: CC
authors.lastname: Hofmeister
authors.forename: Nita
authors.initials: N
authors.lastname: Williams
authors.forename: Susan
authors.initials: S
authors.lastname: Geyer
authors.forename: Erinn M
authors.initials: EM
authors.lastname: Hade
authors.forename: Mindy A
authors.initials: MA
authors.lastname: Bowers
authors.forename: Christian T
authors.initials: CT
authors.lastname: Earl
authors.forename: John
authors.initials: J
authors.lastname: Vaughn
authors.forename: Anissa
authors.initials: A
authors.lastname: Bingman
authors.forename: Kristina
authors.initials: K
authors.lastname: Humphries
authors.forename: Gerard
authors.initials: G
authors.lastname: Lozanski
authors.forename: Robert A
authors.initials: RA
authors.lastname: Baiocchi
authors.forename: Samantha M
authors.initials: SM
authors.lastname: Jaglowski
authors.forename: Kristie
authors.initials: K
authors.lastname: Blum
authors.forename: Pierluigi
authors.initials: P
authors.lastname: Porcu
authors.forename: Joseph
authors.initials: J
authors.lastname: Flynn
authors.forename: Sam
authors.initials: S
authors.lastname: Penza
authors.forename: Don M
authors.initials: DM
authors.lastname: Benson
authors.forename: Leslie A
authors.initials: LA
authors.lastname: Andritsos
authors.forename: Steven M
authors.initials: SM
authors.lastname: Devine
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D002648:Child; D003131:Combined Modality Therapy; D003967:Diarrhea / Q000139:chemically induced; D018572:Disease-Free Survival; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005221:Fatigue / Q000139:chemically induced; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D000069443:Heptavalent Pneumococcal Conjugate Vaccine / Q000008:administration & dosage / Q000276:immunology; D056572:Histone Deacetylase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D006877:Hydroxamic Acids / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008223:Lymphoma / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D008231:Lymphopenia / Q000139:chemically induced; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D011788:Quality of Life; D012008:Recurrence; D014182:Transplantation, Autologous; D016896:Treatment Outcome; D014611:Vaccination / Q000379:methods; D000077337:Vorinostat
chemical_list: D000069443:Heptavalent Pneumococcal Conjugate Vaccine; D056572:Histone Deacetylase Inhibitors; D006877:Hydroxamic Acids; D000077337:Vorinostat
keywords: Chemotherapeutic approaches; lymphoma and Hodgkin disease; vaccines